EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Jump-starting chimeric antigen receptor-T cells to go the extra mile with nanotechnology

Neil C Chada, John T Wilson

Current Opinion in Biotechnology · 2024-10 · 89 · 103179

DOI: 10.1016/j.copbio.2024.103179 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Opinion in Biotechnology, 2024-10. Verfasst von Neil C Chada und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, USA; Medical Scientist Training Program, Vanderbilt University Scho…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Nanotechnology, Immunotherapy, Adoptive, Tumor Microenvironment. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Cancer Institute, National Institute of General Medical Sciences, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite success in treating hematologic malignancies, chimeric antigen receptor-T cell (CAR-T) therapy still faces multiple challenges that have halted progress, especially against solid tumors. Recent advances in nanoscale engineeirng provide several avenues for overcoming these challenges, including more efficienct programming of CAR-Ts ex vivo, promoting immune responsiveness in the tumor microenvironment (TME) in vivo, and boosting CAR-T function in situ. Here, we summarize recent innovations that leverage nanotechnology to directly address the major obstacles that impede CAR-T therapy from reaching its full potential across various cancer types. We conclude with a commentary on the state of the field and how nanotechnology can shape the future of CAR-T and adoptive cell therapy in immuno-oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNanotechnologyImmunotherapy, AdoptiveTumor MicroenvironmentNeoplasmsHumansAnimalsT-LymphocytesReceptors, Antigen, T-Cell

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, USA; Medical Scientist Training Program, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
  • Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, USA; Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN 37235, USA; Vanderbilt Institute for Infec…

Förderung

  • National Cancer Institute
  • National Institute of General Medical Sciences
  • National Institutes of Health

Zitieren

APA

Chada, N. C., & Wilson, J. T. (2024). Jump-starting chimeric antigen receptor-T cells to go the extra mile with nanotechnology. Current Opinion in Biotechnology, 89, 103179. https://doi.org/10.1016/j.copbio.2024.103179

Vancouver

Chada NC, Wilson JT. Jump-starting chimeric antigen receptor-T cells to go the extra mile with nanotechnology. Current Opinion in Biotechnology. 2024;89:103179. doi:10.1016/j.copbio.2024.103179

BibTeX
@article{Chada2024,
  author = {Chada, Neil C and Wilson, John T},
  title = {Jump-starting chimeric antigen receptor-T cells to go the extra mile with nanotechnology},
  journal = {Current Opinion in Biotechnology},
  year = {2024},
  volume = {89},
  pages = {103179},
  doi = {10.1016/j.copbio.2024.103179}
}
Kostenlos starten →